Semaglutide Peptide Dose: Separating Fact from Common Misconception

The biggest misconception: a low starting dose means weak treatment

Many people see 0.25 mg on their first pen and assume they have been given a diluted or ineffective version of the medicine. That is not what is happening. The starting dose of semaglutide has one job: to let your gut, and the hormonal pathways semaglutide activates, settle into the new signal without being overwhelmed. Nausea and other gastrointestinal effects are more pronounced when the dose climbs too quickly, so the slow introduction is a deliberate clinical strategy, not a cautious half-measure.

The 0.25 mg level is not the therapeutic target. It is the foundation that makes reaching the therapeutic dose (2.4 mg, or higher) as comfortable as possible. Most people tolerate the lower steps well enough to move up every four weeks, but if you find a particular step difficult, your prescriber can hold you there longer. That flexibility is part of the design. The full semaglutide dose pathway from start to maintenance reflects years of titration research built into the Wegovy licence.

A question our prescribers hear regularly is whether skipping ahead would get results faster. The clinical answer is no: moving to a higher dose before your system has adjusted increases the likelihood of side effects that may cause you to stop treatment altogether, which achieves nothing. Patience with the schedule is genuinely part of the medicine.

What the licensed semaglutide peptide dosage chart looks like

The standard Wegovy titration runs in four stages, each lasting roughly four weeks: 0.25 mg, then 0.5 mg, then 1.0 mg, then 1.7 mg, reaching the 2.4 mg maintenance dose by around week 17 for most people. If 2.4 mg is not tolerated, 1.7 mg can serve as a maintenance dose under prescriber guidance. The Wegovy dosing overview covers each step in plain terms.

Since January 2026 there has been a further licensed option. The MHRA approved a 7.2 mg maintenance dose for adults with a BMI of 30 or above, and in April 2026 a dedicated single-dose 7.2 mg pen received regulatory clearance. In trial data, this higher dose produced around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide at its highest strength. The starting point remains 0.25 mg regardless, there is no short route to 7.2 mg, and your prescriber would assess suitability before any move to this level. For context on how that compares with the wider injectable options available, the Wegovy overview page sets out the full picture.

It is worth knowing that the semaglutide peptide dosage chart described here applies specifically to Wegovy for weight management. Ozempic contains the same molecule but is licensed for type 2 diabetes at different doses, the two are not interchangeable, and Ozempic is not licensed or appropriate for weight loss. The NHS medicines information for semaglutide covers both indications clearly, and NHS guidance on semaglutide is the clearest public-facing reference for the distinction.

Side effects across the dose schedule: what typically happens at each stage

Gastrointestinal effects (nausea above all, followed by diarrhoea, constipation and reflux) are most likely in the first week after a dose increase, because each step represents a new signal strength for the gut. For most people the discomfort is mild and passes within a few days to two weeks as the body adjusts. Eating smaller portions, avoiding high-fat meals and staying well hydrated all help. The STEP 1 trial, published in the New England Journal of Medicine, documented this side-effect profile across 68 weeks in over 1,900 adults, the majority of GI events were mild or moderate and transient.

More serious signals to take seriously: severe, persistent abdominal pain that spreads to the back should prompt same-day medical attention, as this can indicate pancreatitis. Symptoms of an allergic reaction, sudden changes in vision, or signs of dehydration after prolonged vomiting or diarrhoea also warrant urgent contact with a clinician. If you are taking an oral contraceptive pill whilst on semaglutide, absorption of the pill is not thought to be significantly affected in the same way as with tirzepatide, but it is always worth raising this with your prescriber, particularly at dose increases.

Suspected side effects can be reported directly through the MHRA's Yellow Card scheme, which helps regulators monitor real-world safety data for medicines like Wegovy that carry the Black Triangle (▼) status, meaning additional post-marketing surveillance applies.

Who the Wegovy dosage schedule applies to, and what a clinical review considers

The licensed eligibility for semaglutide as Wegovy covers adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, raised cholesterol or obstructive sleep apnoea. Lower thresholds of 2.5 kg/m² apply for South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds under UK guidance.

BMI meeting the threshold is necessary but not sufficient. A prescriber will also consider your medical history, current medicines, any conditions that would make semaglutide unsuitable, and whether you are pregnant, breastfeeding or planning to conceive, Wegovy is not recommended in any of those circumstances, or for people under 18. People who are curious about what this assessment involves and what to expect can find detail on the weight-loss treatment consultation page.

For those researching how semaglutide compares with combination approaches, there is growing clinical interest in peptide pairings, and if you want to understand the peptide formulations sitting behind these treatments, our pages on 5mg semaglutide peptide and 10 mg semaglutide peptide explain what each involves. Cagrilintide combined with semaglutide is one area of active investigation, though at the time of writing it is not yet licensed in the UK. The treatment landscape is moving quickly, and a prescriber is the right person to help you make sense of it for your specific situation. Starting with a free consultation is the straightforward first step.